Sanofi

Harvard scientists developed TxGNN, an AI tool for drug repurposing, focusing on multiple diseases to aid rare conditions. Pharma leaders discussed clinical trial quality at SCOPE Europe. Placental pathology integration into trials was advocated for better pregnancy condition insights. AI regulation's impact on life sciences was debated. Ensuring participant adherence in trials using wearables was emphasized.

The clinical trial ecosystem is evolving with increased data analytics, electronic health records, and patient-centricity, driving collaboration and data sharing. Technologies like IoT and wearables improve data collection and patient experience. Platforms like the Oncology Clinical Trial Information Commons enhance data sharing. Patient-facing technologies and integrated research organizations aim for better collaboration and patient care. The shift towards prevention over cure introduces new players. Automation improves site selection, and partnerships between sponsors and CROs strengthen. Pharmaceutical physicians now engage more with patients, and hospitals collaborate with pharma manufacturers, reflecting a move towards integrated, efficient clinical research.

The multiple myeloma (MM) market is expected to grow significantly, driven by monoclonal antibodies elotuzumab and daratumumab. MM, a blood cancer, affects bone marrow and blood cell production. Treatments include chemotherapy, biologic therapy, and stem-cell transplant. New drugs like elotuzumab and daratumumab are anticipated to extend relapse intervals and increase treatment accessibility.

A multicenter retrospective analysis evaluated combination systemic therapies in 253 nccRCC patients from 2012-2024. Results showed limited antitumor activity, with differential responses among nccRCC subsets based on regimen type. Optimal nccRCC management remains an unmet need, highlighting the necessity for further research.

LEAP-012 trial showed len + pembro + TACE significantly improved PFS vs placebo + TACE in intermediate-stage HCC patients. OS data were immature, with a trend toward improvement. Safety profiles were consistent with known effects of the treatments. OS will be reassessed in future analyses.

Myelofibrosis (MF) is a severe myeloproliferative neoplasm characterized by dysregulated JAK/STAT signaling, leading to symptoms like splenomegaly and anemia. Ruxolitinib, a JAK1/JAK2 inhibitor, is approved for MF treatment, improving spleen size and symptoms but not reversing bone marrow fibrosis. Ongoing research explores combination therapies and new agents targeting anemia and fibrosis.